Assurex Health is a personalized medicine company that specializes in helping physicians determine the right medication for individual patients who have Behavioral Health disorders.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

news image

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More

Research

PRISM BIOLAB, ENTERS MULTI-PROJECT DRUG DISCOVERY COLLABORATION WITH ROCHE AND GENENTECH

PRISM BioLab Co., Ltd. | January 05, 2022

news image

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon id...

Read More

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

PR.com | January 20, 2020

news image

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More

Industrial Impact

IVERIC BIO AND DELSITECH ENTER EXCLUSIVE AGREEMENT FOR DEVELOPMENT OF SUSTAINED RELEASE ZIMURA®

IVERIC bio, Inc. | July 06, 2022

news image

IVERIC bio, Inc. and DelSiTech Ltd, announced an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD). These technologies potentially could address patients ...

Read More
news image

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More
news image

Research

PRISM BIOLAB, ENTERS MULTI-PROJECT DRUG DISCOVERY COLLABORATION WITH ROCHE AND GENENTECH

PRISM BioLab Co., Ltd. | January 05, 2022

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon id...

Read More
news image

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

PR.com | January 20, 2020

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More
news image

Industrial Impact

IVERIC BIO AND DELSITECH ENTER EXCLUSIVE AGREEMENT FOR DEVELOPMENT OF SUSTAINED RELEASE ZIMURA®

IVERIC bio, Inc. | July 06, 2022

IVERIC bio, Inc. and DelSiTech Ltd, announced an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD). These technologies potentially could address patients ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us